IL-6 to the rescue? Sanofi, Regeneron barrel ahead into another pivotal effort testing Kevzara for Covid-19

John Carroll

Editor & Founder

Sanofi and Regeneron have hustled up a second pivotal trial for their IL-6 drug Kevzara as a potential therapy for severe cases of Covid-19. The partners swiftly assembled a study drawing patients from Italy, Spain, Germany, France, Canada and Russia, planning to sign up 300 patients in a Phase II to test a low and high dose of Kevzara against placebo, setting the stage for the Phase III followup.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

IL-6 to the rescue? Sanofi, Regeneron barrel ahead into another pivotal effort testing Kevzara for Covid-19

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

FDA unveils new rare disease pilot program to increase agency-sponsor communications

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

Data Quality 2.0: The Future of Real-World Evidence

IL-6 to the res­cue? Sanofi, Re­gen­eron bar­rel ahead in­to an­oth­er piv­otal ef­fort test­ing Kevzara for Covid-19

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

De­spite a sum­mer of block­buster rounds, biotech fund­ing is on track to lev­el off at pre-pan­dem­ic norms

FDA rolls out long-await­ed pro­pos­al to over­haul di­ag­nos­tics reg­u­la­tion

FDA un­veils new rare dis­ease pi­lot pro­gram to in­crease agency-spon­sor com­mu­ni­ca­tions

In the race to get type 1 pa­tients off in­sulin, fo­cus turns to cell trans­plants and in­sulin-pro­duc­ing stem cells

How aca­d­e­m­ic cen­ters are try­ing to keep their promis­ing drug dis­cov­er­ies out of the ‘val­ley of death’

Da­ta Qual­i­ty 2.0: The Fu­ture of Re­al-World Ev­i­dence

IL-6 to the rescue? Sanofi, Regeneron barrel ahead into another pivotal effort testing Kevzara for Covid-19

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

FDA unveils new rare disease pilot program to increase agency-sponsor communications

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

Data Quality 2.0: The Future of Real-World Evidence